Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
RESEARCH TOOLSreports
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.87Last Year’s EPS
1.45Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 0.07%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in Jornay PM and a strong financial position, supported by strategic acquisitions and expansions. Despite a decline in Nucynta revenue and increased operating expenses, the overall outlook remains positive due to strong performance in the pain portfolio and strategic initiatives.Company Guidance
During Collegium Pharmaceuticals' fourth quarter and full year 2024 earnings call, the company provided substantial guidance for 2025. They anticipate significant growth, with net product revenues expected to range between $735 million and $750 million, primarily driven by Jornay, which is projected to achieve net revenues exceeding $135 million, representing over 34% growth. For 2024, Collegium reported an 11% increase in total revenue and a 9% growth in adjusted EBITDA. The company also highlighted the expansion of its sales force from 125 to 180 representatives to enhance Jornay's market penetration. Additionally, they discussed expectations for net leverage to fall below one times by the end of 2025. The company plans to continue strategic capital deployment, including share repurchases and debt reduction, while focusing on maximizing the potential of its pain portfolio and expanding through business development.Strong Growth in Jornay PM
Jornay prescriptions grew 29% year-over-year and 11% quarter-over-quarter in Q4 2024. Net revenue was $100.7 million in 2024, expected to exceed $135 million in 2025, representing over 34% growth.
Record Revenues for Pain Portfolio
The pain portfolio generated 5% revenue growth in 2024, with record revenues for both BELBUCA and Xtampza ER. Total revenue grew 11%, and adjusted EBITDA grew 9% year-over-year.
Strategic Acquisitions and Expansions
Acquired Ironshore Therapeutics and its lead medicine Jornay PM, establishing a presence in neuropsychiatry. Expanded sales force from 125 to 180 to increase coverage for Jornay.
Positive Developments for Nucynta Franchise
Projected exclusivity for Nucynta ER extended to July 2027, reinforcing it as a robust revenue contributor.
Strong Financial Position
Ended 2024 with net leverage of less than two times and expect to end 2025 with net leverage of less than one time.
---
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
COLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $28.42 | $29.05 | +2.22% |
| Nov 07, 2024 | $34.71 | $32.16 | -7.35% |
| Aug 08, 2024 | $35.32 | $35.50 | +0.51% |
| May 09, 2024 | $37.86 | $31.50 | -16.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Collegium Pharmaceutical (COLL) report earnings?
Collegium Pharmaceutical (COLL) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Collegium Pharmaceutical (COLL) earnings time?
Collegium Pharmaceutical (COLL) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COLL EPS forecast?
COLL EPS forecast for the fiscal quarter 2025 (Q1) is 1.87.
---